Nurix Therapeutics to Host Webcast on Clinical Trial Insights
Nurix Therapeutics, Inc. (NASDAQ: NRIX), a pioneering biopharmaceutical company dedicated to delivering innovative treatments for cancer and inflammatory diseases, is excited to announce an upcoming live webcast. This session will shed light on newly available clinical data from their Phase 1a/1b clinical trial involving NX-5948, a groundbreaking BTK degrader. Set for 8:15 p.m. PT, the webcast will take place on December 9, inviting attendees from both the scientific community and the public to gain insights into the latest advancements.
Webcast Presentation Details
The evening’s presentation will be particularly insightful, featuring Dr. Nirav N. Shah, M.D., M.S.H.P., associated with the Medical College of Wisconsin, who is a vital clinical investigator in the study. Dr. Shah will present key findings from the ongoing trial of NX-5948, aimed at treating patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Additionally, leadership from Nurix including Arthur T. Sands, M.D., Ph.D. (President and CEO), Paula G. O’Connor, M.D. (Chief Medical Officer), and Gwenn M. Hansen, Ph.D. (Chief Scientific Officer) will discuss Nurix’s broader clinical development strategy for NX-5948 across oncology and autoimmune conditions.
About NX-5948
NX-5948 is an investigational agent designed as an orally bioavailable and brain-penetrable small molecule that specifically degrades BTK, a protein crucial for B-cell growth signaling. The goal of NX-5948 is to address the limitations seen with existing BTK inhibitor therapies, especially for patients who are heavily pretreated and show resistance to current treatment modalities. Early trials have indicated that NX-5948 is highly effective against various tumor cell lines, signaling a promising avenue for those battling B-cell malignancies.
Introducing Nurix Therapeutics
Nurix Therapeutics is at the forefront of biopharmaceutical innovation, focusing on the modulation of cellular protein levels as a novel therapeutic approach for serious diseases. With a robust pipeline that includes targeted protein degraders and inhibitors, Nurix is utilizing its expertise in E3 ligases to develop therapies that impact both cancer and inflammatory conditions significantly. Their DELigase discovery platform enables the identification and advancement of new drug candidates designed to modify protein levels effectively. This pioneering approach to drug discovery positions Nurix as a leader in the biopharmaceutical landscape, dedicated to bringing new hope to patients with complex health challenges.
Join the Live Webcast
Participants will have the opportunity to access the webcast and subsequent archives via the Nurix Therapeutics website. This event is not only significant for investors but also for healthcare professionals interested in the latest advancements in cancer treatment.
Frequently Asked Questions
What will be discussed during the Nurix Therapeutics webcast?
The webcast will cover new clinical data from the Phase 1a/1b trial of NX-5948, including insights from Dr. Nirav N. Shah and Nurix's leadership on future strategies.
When is the Nurix Therapeutics webcast scheduled?
The live webcast is scheduled for December 9 at 8:15 p.m. PT.
What is NX-5948?
NX-5948 is an investigational drug that acts as a BTK degrader, targeting B-cell malignancies, particularly in patients who have previously undergone treatment failures.
How does Nurix Therapeutics approach drug discovery?
Nurix focuses on modulating cellular protein levels through its unique DELigase platform to create innovative treatments for cancer and inflammatory diseases.
Where can I watch the webcast?
The live webcast and an archived replay will be available in the Investors section of the Nurix Therapeutics website.
